At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,392 enrolled
Drug / intervention
LY900014 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D
In Brief
A Phase 3 clinical trial evaluating LY900014, Insulin Lispro, and 2 other interventions for Type 1 Diabetes Mellitus. Completed, enrolled 1,392 participants across 172 sites in 20 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes Mellitus
CountriesArgentina, Australia, Austria, Brazil, Germany, Greece, India, Italy, Japan, Mexico, New Zealand, Poland, Puerto Rico, Romania, Russia, Slovakia, Spain, Sweden, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartJul 2017
Primary CompletionSep 2018
Study CompletionAug 2019
TodayJul 2026
First PostedJul 11, 2017
Enrollment StartJul 17, 2017
Primary CompletionSep 6, 2018
Study CompletionAug 22, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.0 years ago
Interventions
LY900014drug
Administered SC
Insulin Lisprodrug
Administered SC
Insulin Glarginedrug
Administered SC
Insulin Degludecdrug
Administered SC